Table 2.
COPD maintenance medication
| Drug | Device | Formulation | Strength US | Strength EU |
|---|---|---|---|---|
| SABA | ||||
| Levalbuterol | MDI | Aerosol, metered | 45 mcg | Not available |
| Nebulizer | Solution | 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/0.5 mL, 1.25 mg/3 mL | Not available | |
| Salbutamol (albuterol) | MDI | Aerosol, metered | 90 mcg | 100 mcg |
| SAMA | ||||
| Ipratropium bromide | MDI | Aerosol, metered | 17 mcg | 20 mcg |
| Nebulizer | Solution | 500 mcg/2.5 mL | 250 mcg/1 mL, 500 mcg/2 mL | |
| SABA + SAMA | ||||
| Fenoterol/ipratropium | Nebulizer | Solution | Not available | 0.5/1.25 mg/4 mL |
| MDI | Aerosol, metered | 20/50, 250/500 mcg | ||
| Salbutamol/ipratropium | SMI | Spray | 100/20 mcg | Not available |
| Nebulizer | Solution | Not available | 3/0.5 mg/2 mL | |
| LABA | ||||
| Arformoterol | Nebulizer | Solution | 15 mcg/2 mL | Not available |
| Formoterol | DPI | Capsule | 12 mcg | 4.5, 6, 9, 12 mcg |
| Nebulizer | Solution | 20 mcg/2 mL | Not available | |
| Indacaterol | DPI | Capsule | 75 mcg | 150, 300 mcg |
| Olodaterol | SMI | Spray, metered | 2.5 mcg | 2.5 mcg |
| Salmeterol | DPI | Powder, metered | 50 mcg | 25, 50 mcg |
| LAMA | ||||
| Aclidinium bromide | DPI | Powder, metered | 400 mcg | 322 mcg |
| Glycopyrronium bromide | DPI | Capsule | 15.6 mcg | 44 mcg |
| Tiotropium | DPI | Capsule | 18 mcg | Not available |
| SMI | Spray, metered | 1.25, 2.5 mcg | 2.5 mcg | |
| Umeclidinium | DPI | Powder, metered | 62.5 mcg | 55 mcg |
| LABA + LAMA | ||||
| Formoterol/Aclidinium | DPI | Powder, metered | 400/12 mcg | 340/12 mcg |
| Formoterol/Glycopyrronium | MDI | Aerosol, metered | 4.8/9 mcg | 5/7.2 mcg |
| Indacaterol/Glycopyrronium | DPI | Capsule | 27.5/15.6 mcg | 85/43 mcg |
| Vilanterol/Umeclidinum | DPI | Powder, metered | 25/62.5 mcg | 22/55 mcg |
| Olodaterol/Tiotropium | SMI | Spray, metered | 2.5/2.5 mcg | 2.5/2.5 mcg |
| LABA + ICS | ||||
| Formoterol/Beclomethasone | MDI | Aerosol | Not available | 6/100 mcg |
| DPI | Powder | Not available | 6/100 mcg | |
| Formoterol/Budesonide | MDI | Aerosol | 4.5/80, 4.5/160 mcg | 4.5/80, 4.5/160, 9/230 mcg |
| Formoterol/Momestasone | MDI | Aerosol | 5/100, 5/200 mcg | Not available |
| Vilanterol/Fluticasone | DPI | Powder, metered | 25/100, 25/200 mcg | 100/25 mcg, 200/25 mcg |
| Salmeterol/Fluticasone | DPI | Capsule | 50/100, 50/250, 50/500 mcg | 50/500 mcg |
| MDI | Aerosol, metered | 14/55, 14/113, 14/232, 21/45, 21/115, 21/230 mcg | Not available | |
| LABA + LAMA + ICS | ||||
| Vilanterol/Umeclidinium/Fluticasone | DPI | Powder, metered | 25/62.5/100 mcg | 22/55/92 mcg |
| Formoterol/Glycopyrronium/Beclometasone | MDI | Aerosol | Not available | 5/9/87 mcg |
| PDE4 Inhibitor | ||||
| Roflumilast | — | Tablet | 500 mcg | 500 mcg |
COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; EU, European Union; ICS, inhaled corticosteroid; LABA, long‐acting β2‐adrenoreceptor agonist; LAMA, long‐acting muscarinic antagonist; MDI, metered dose inhaler; PDE4, phosphodiesterase type 4; SABA, short‐acting β2‐adrenoreceptor agonist; SAMA, short‐acting muscarinic antagonist; SMI, soft mist inhaler; US, United States.